Notably, COX-2 overexpression has been found in a variety of sarcomas and has been associated with poor prognosis [14,15,16], thus suggesting that COX-2 inhibitors could play a role in NF1 cancer prevention. The gene discussed is PTGS2; the disease is neurofibromatosis type 1.